ALRTF · XBRL financial data
ALR Technologies SG financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ALRTF's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Revenue | 2 | 26 | — | — |
| Revenue from contracts with customers | 2 | 26 | — | — |
| Cost of revenue | 1 | 22 | — | — |
| Gross profit | 1 | 3 | — | — |
| Research and development | 482 | 1,404 | 884 | 793 |
| Selling, general and administrative | 2,867 | 2,598 | 2,016 | 1,471 |
| Total operating expenses | 4,270 | 4,817 | 3,412 | 2,882 |
| Operating income (loss) | 4,270 | — | — | — |
| Interest expense | 6,350 | 2,522 | (12,424) | (19,736) |
| Other income (expense) | — | — | (41) | — |
| Net income (loss) | (10,619) | (7,475) | (15,878) | (22,058) |
| Earnings per share, basic USD per share | (0.02) | (0.01) | (0.03) | — |
| Earnings per share, diluted USD per share | (0.02) | (0.01) | (0.03) | (0.04) |
| Weighted average shares, basic thousands of shares | 548,079 | 581,016 | 598,924 | — |
| Weighted average shares, diluted thousands of shares | 548,079 | 581,016 | 598,924 | 606,994 |
Balance sheet
CSVFiscal years (ALRTF's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | 149 | 59 | 41 | 20 |
| Accounts receivable | — | 41 | — | — |
| Inventory | — | 11 | 11 | 11 |
| Total assets | 377 | 155 | 79 | 47 |
| Accounts payable | 1,054 | 1,180 | 1,679 | 1,292 |
| Accrued liabilities | 289 | 318 | 300 | 101 |
| Total current liabilities | 27,089 | 32,071 | — | — |
| Total liabilities | 28,932 | 32,071 | 36,303 | 39,906 |
| Accumulated deficit | (112,634) | (120,108) | (135,986) | (158,044) |
| Total stockholders' equity | (28,555) | (31,916) | (36,224) | (39,859) |
| Total liabilities and equity | 377 | 155 | 79 | 47 |
| Common shares outstanding (cover page) thousands of shares | 551,967 | 632,467 | 635,467 | 645,467 |
Cash flows
CSVFiscal years (ALRTF's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Net income (loss) | (10,619) | (7,475) | (15,878) | (22,058) |
| Stock-based compensation | 4,005 | — | — | — |
| Net cash from operating activities | (2,078) | (1,622) | (1,540) | (1,868) |
| Proceeds from issuing common stock | 0 | 745 | — | — |
| Net cash from financing activities | 2,011 | 1,539 | 1,521 | 1,848 |
| Net change in cash | 33 | (90) | (18) | (20) |
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| ALR Technologies SG | 20 | not reported | year only | 645.5M | — | 20-FDec 31, 2025 |
| Adagio Medical Holdings | 7,740 | 0 | (5,260)* | 22.2M | 1.5 quarters | 10-QJun 30, 2026 |
| Aethlon Medical | 4,934 | not reported | (1,897) | 711,136 | 2.6 quarters | 10-QJun 30, 2026 |
| Acutus Medical | 14,019 | 7,130* | (4,058)* | 29.9M | 3.5 quarters | 10-KDec 31, 2024 |
| Allurion Technologies | 5,056 | 2,947 | (3,221) | 15.0M | 1.6 quarters | 10-QMar 31, 2026 |
| Autonomix Medical | 3,460 | 0 | (3,544) | 971,043 | 1.0 quarters | 10-QJun 30, 2026 |
| Angiodynamics | 33,973 | 80,915 | (15,330) | 42.1M | 2.2 quarters | 10-QAug 31, 2026 |
| Anika Therapeutics | 38,412 | 32,610 | (684)* | 13.4M | 56.2 quarters | 10-QJun 30, 2026 |
| Artivion | 77,316 | 125,757 | (1,266)* | 48.8M | 61.1 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.